Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 2009 Derek Lowe	Column: In the pipeline The author wonders where we'd be without the formulation chemists
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
Chemistry World June 1, 2012 Derek Lowe	Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.
Chemistry World June 2008	Column: In the pipeline The author, a medicinal chemist working on preclinical drug discovery, takes a look at the differences between chemists and biologists working on the same team.
Chemistry World October 2008 Derek Lowe	Column: In the pipeline The author seeks a cure for 'compound bloat'
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World November 2009 Derek Lowe	Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
Chemistry World July 30, 2015 Derek Lowe	A precision instrument? How much do medicinal chemists and their biology colleagues really trust each other's data? In the end, they have to, because drug discovery is a team sport.
Chemistry World November 2008 Derek Lowe	Column: In the pipeline Drug discovery chemists live by assay data; we depend on these numbers to tell us if we're heading in the right direction with our molecules.
Chemistry World September 25, 2015 Derek Lowe	Spice up your compounds You and your team are optimizing a lead compound, as medicinal chemists are wont to do -- varying its structure to improve its potency, selectivity and other properties.
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
Chemistry World August 2008	Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?
Chemistry World May 26, 2011 Rebecca Brodie	Nanospray for nanodrugs Teams from the US and Germany have developed a spray drying technique to fabricate drug formulations smaller than 100nm for pharmaceutical trials, improving the drugs' solubility, or bioavailability.
Chemistry World August 2011	Column: In the pipeline Derek Lowe highlights the less visible pitfalls on the road to a new drug
Chemistry World March 23, 2010	Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann
Chemistry World January 2011	Column: In the pipeline Some medicinal chemists can't get enough fluorines in their molecules. The love-hate relationship is explained.
Chemistry World February 14, 2011 Catherine Bacon	New hepatitis C drug Scientists in the UK have developed a compound to combat the hepatitis C virus that could be taken as a pill.
Chemistry World November 28, 2013	Put the chemistry back in medicinal chemistry Today, synthetic skill is valued and appreciated much less in medicinal chemistry than in chemical development, though it is equally important for both. Much of the blame lies with the mismeasurement of productivity.
Chemistry World June 17, 2015 James Urquhart	Promising compound offers single dose knock-out for malaria Ian Gilbert and colleagues, working with the Medicines for Malaria Venture, have found a compound dubbed DDD107498 which kills Plasmodium falciparum -- the species responsible for most dangerous form of malaria.
Bio-IT World August 18, 2004 Kevin Davies	In Praise of Chemical Diversity How to build better small-molecule libraries.
Chemistry World November 2006 Derek Lowe	Opinion: In the Pipeline Is there a way to kill off bad drug candidates before companies invest valuable time and money and in them?
Chemistry World March 2012	Column: In the pipeline Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
Chemistry World April 2008 Derek Lowe	Column: In the Pipeline The recent row over antidepressants reminds us how little we know about the brain.
Chemistry World April 2011	Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products.
Chemistry World February 8, 2006 Jon Evans	To Boldly go Where no Chemist Has Gone Before Studying the interactions between different molecular fragments is taking researchers to the uncharted regions of chemical space.
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Chemistry World July 22, 2015 Judy Hayler	The handbook of medicinal chemistry: principles and practice The handbook of medicinal chemistry: principles and practice guides the reader through the R&D process from target validation to late stage clinical trials, via a series of chapters written by individuals in industry and academia.
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World May 13, 2015 Stephen McCarthy	Venoms to drugs: venom as a source for the development of human therapeutics The book is well-constructed, starting with an overview of the evolutionary origins of venoms and how these relate to common structures, followed by a guide to modern bioinformatics methods and their application to research in this field.
Chemistry World March 27, 2014 Derek Lowe	Known unknowns Most dangerous substances announce themselves by their structures and reactivity, and a competent organic chemist should be able to read those signs.
Chemistry World November 30, 2012 Andy Extance	Chemists cull compounds using 'intuition' Medicinal chemists might be using far fewer parameters to choose candidate fragments for a screening collection than they think they do. Their choices can be mimicked based on just one or two properties, a team led by researchers at Swiss-headquarted pharmaceutical firm Novartis has found.
Chemistry World October 2009	Column: In the pipeline Derek Lowe discusses the problem of leaning too heavily on favorite reactions
Chemistry World July 21, 2010 Lewis Brindley	Selenium-based quinones show anticancer promise The new compounds have great potential for future cancer therapy, and early studies show similar activity to the well-known chemotherapy drug cisplatin, although a selenium-based therapy would cost a fraction of the price.
Chemistry World December 2007 Derek Lowe	Column: In the Pipeline The challenge of biologics.
Chemistry World January 14, 2015 Derek Lowe	Ignorance is no defense Chemists can be a danger to themselves and others if they don't know enough about the compounds they're working with.
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
Chemistry World April 25, 2013 Andreas Barth	Chemical bibliometrics Counting compounds instead of publications and citations opens new perspectives for data-based scientific discovery and it can complement and stimulate both experimental and theoretical research.
The Motley Fool April 2, 2007 Brian Lawler	A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
Chemistry World June 18, 2015 Emma Stoye	Crowdsourcing compounds to tackle antibiotic resistance Chemists around the world are being called on to donate samples of novel compounds they have synthesized to a crowdsourcing project that aims to find new antibiotics.
Reactive Reports November 2007 David Bradley	Organic Uranium The first ever uranium methylidyne molecule has been synthesized by US chemists despite the reactivity of the heavy, heavy metal.
HHMI Bulletin Nov 2011 Sarah C. P. Williams	Living Chemistry Biologists understand better what chemists can bring to the table. And chemists understand better the questions that biologists really care about. This has led to a bigger impact of chemists on biological problems.
Chemistry World April 2007 Derek Lowe	Opinion: In the Pipeline Natural products can be ridiculously complicated. The sheer difficulty of the enterprise is traditionally what made pharmaceutical companies hire people who had worked in total synthesis. But, is total synthesis research still worth the effort?